Atossa Therapeutics Q3 net loss narrows as clinical trial expenses decline

Atossa Therapeutics

10/11/2026 13:23

Overview
US biopharmaceutical company reported Q3 net loss narrowed from prior year period
Q3 operating expenses fell due to lower clinical trial and legal costs
Company announced contingent value rights tied to potential future priority review voucher monetization

Outlook
Atossa expects FDA IND clearance for (Z)-endoxifen in MAS and DMD by early 2027
Company expects topline data from Phase 2 EVANGELINE study in Q2 2027
Select data from I-SPY2 study to be presented at SABCS in December 2026

Result Drivers
LOWER CLINICAL TRIAL SPEND - Co said decline in clinical trial expenses was due to completion of enrollment in (Z)-endoxifen studies
LOWER LEGAL FEES - Co attributed reduced G&A expenses to lower legal fees following resolution of patent litigation

Company press release: ID:nPn2kPGLSa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Loss Per Share
 
$0.56
 
Q3 Net Loss
 
$5.64 mln
 
Q3 Operating Expenses
 
$5.9 mln
 
Q3 Operating Income
 
-$5.9 mln
 
Q3 Pretax Loss
 
$5.64 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Atossa Therapeutics Inc is $22.00, about 932.9% above its November 9 closing price of $2.13

Reuters Recommended Reads
Nov 10 - Corbus Pharmaceuticals Q3 net loss widens on higher expenses
Nov 9 - Perspective Therapeutics Q3 net loss widens on higher R&D costs
Nov 10 - PMV Pharmaceuticals Q3 net loss widens on warrant charges

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)